We define CD34+CD38− AML cells as LSCs, and FACS analysis showed that the majority (74 ± 25.3%) of LSCs expressed CD96, while only a minority (4.9 ± 1.6%) of normal hematopoietic stem cells (HSC) weakly expressed CD96. This evidence concerns the gene CD96 and acute myeloid leukemia.